Explore the Potential with AI-Driven Innovation
The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.
Several key aspects differentiate our library:
partner
Reaxense
upacc
Q99707
UPID:
METH_HUMAN
Alternative names:
5-methyltetrahydrofolate--homocysteine methyltransferase; Cobalamin-dependent methionine synthase; Vitamin-B12 dependent methionine synthase
Alternative UPACC:
Q99707; A1L4N8; A9Z1W4; B7ZLW7; B9EGF7; Q99713; Q99723
Background:
Methionine synthase, also known as 5-methyltetrahydrofolate--homocysteine methyltransferase, plays a pivotal role in methionine biosynthesis by transferring a methyl group from methylcob(III)alamin to homocysteine, yielding methionine. This process is vital for DNA synthesis and repair, implicating the protein in crucial cellular functions.
Therapeutic significance:
The protein's malfunction is linked to Homocystinuria-megaloblastic anemia, cblG complementation type, and Neural tube defects, folate-sensitive, highlighting its therapeutic potential. Understanding the role of Methionine synthase could open doors to potential therapeutic strategies for these conditions.